Viking Therapeutics Gains Momentum with Insider Purchase and Advancing Pipeline

Viking's new commercial chief buys stock as the firm outlines 2026 Phase 3 plans for its obesity drug VK2735, both injectable and oral, backed by a strong cash position.

A recent insider purchase and detailed updates on its clinical programs have brought Viking Therapeutics back into the spotlight. The company’s newly appointed commercial chief has made a significant personal investment, while a clear development timeline for its obesity treatment portfolio was outlined at a major industry conference.

Commercial Chief Demonstrates Confidence with Personal Investment

Neil Aubuchon, who joined Viking Therapeutics as Chief Commercial Officer in January 2026, has made his first open-market purchase of the company's stock since taking the role. On March 10, he acquired 4,475 shares at an average price of $33.50, representing a total investment of nearly $150,000.

While such transactions are not a guarantee of future share performance, market observers often view them as a meaningful signal. Aubuchon’s purchase is seen as a demonstration of personal conviction in the company's prospects, particularly as he will be responsible for guiding the commercial strategy for its lead asset, VK2735.

Dual-Track Development for Flagship Obesity Drug

Viking’s central drug candidate, VK2735, is progressing simultaneously through two distinct formulation pathways: subcutaneous injection and oral administration.

The subcutaneous version is already in two pivotal Phase 3 trials. The VANQUISH-1 study has enrolled approximately 4,650 participants, while VANQUISH-2 plans to include about 1,100. Results from both trials are anticipated during the course of 2026. These studies follow a Phase 2 trial named VENTURE, which demonstrated weight reductions of up to 14.7% without a clear plateau effect.

Meanwhile, the oral formulation of VK2735 has received clearance from the U.S. Food and Drug Administration (FDA) to proceed into Phase 3 development, with initiation targeted for the third quarter of 2026. A notable aspect of the oral program is its design, which aims to require 75% fewer patients than the subcutaneous studies, potentially leading to substantially lower development costs. Additionally, data from a Phase 1 study investigating a maintenance dosing regimen, involving roughly 180 participants, is expected in Q3 2026.

Manufacturing Strategy and Financial Position Detailed

During the Leerink Global Healthcare Conference, the biopharmaceutical firm also provided details on its manufacturing and financial footing. Viking has entered into a comprehensive supply agreement with CordenPharma. The pact secures annual production capacity for 100 million vials and syringes, 100 million auto-injectors, and one billion tablets. To secure these capabilities, Viking will make advance payments totaling $150 million between 2025 and 2028.

The company finished 2025 with a solid cash position of $706 million. Its shares have appreciated by 16.3% since the last quarterly report, despite the company posting a larger-than-expected loss in the fourth quarter.

Viking has set a commercial target of capturing 5% to 10% market share in the obesity segment, with an explicit focus on markets outside the United States. With multiple data readouts from both the subcutaneous and oral programs expected before year-end, the company’s calendar for 2026 remains densely packed with potential catalysts.